Administered as a muco-adhesive buccal tablet, Loramyc is an antifungal agent indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients. As per the terms of the agreement,
In addition to the drug-drug, drug-allergy, drug-food and drug-herbal checks, PEPID’s drug interaction checker also provides alerts for duplicate therapy on three different levels -therapeutic class, pharmacologic class
The company has reported a net income of $3.19m, or $0.13 loss per diluted share, compared to net income of $1.86m or $0.08 per diluted share, for the
Developed by Allos, Folotyn is a folate analogue metabolic inhibitor, approved in the US to treat of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The tie
Under the pact, Pfenex will engineer production strains and develop early production processes for MedImmune‘s proprietary molecules. The tie up also allows MedImmune to carry forward the preclinical
The study has evaluated 494 adult patients with UC who had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants. In the trial, 16.5% of the
Under the pact, both the companies will evaluate whether a fixed ratio of pramlintide and insulin can effectively help treat type 1 diabetes. The program will also evaluate
Meta-060 is a proprietary and patented formulation of tetrahydro iso-alpha acids derived from hops. The collaboration is to investigate if genetic variations identified by Interleukin Genetics are beneficial
Resolor is a selective, high-affinity 5-HT4 receptor agonist specifically developed to target impaired motility associated with chronic constipation. Three Phase II dose-finding trials of 280 predominantly female patients
The Phase 3 trial investigated the safety and efficacy of TAK-085 in comparison with an active comparator, EPA (eicosapentaenoic acid) in patients suffering from hypertriglyceridemia. The results of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.